Andrew Polovin Sells 10,949 Shares of Tempus AI (NASDAQ:TEM) Stock

Tempus AI, Inc. (NASDAQ:TEM) EVP Andrew Polovin sold 10,949 shares of the company’s stock in a transaction on Friday, February 20th. The stock was sold at an average price of $60.31, for a total value of $660,334.19. Following the transaction, the executive vice president directly owned 126,918 shares in the company, valued at $7,654,424.58. This represents a 7.94% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

Andrew Polovin also recently made the following trade(s):

• On Thursday, February 19th, Andrew Polovin sold 8,143 shares of Tempus AI stock. The shares were sold at an average price of $59.05, for a total value of $480,844.15.
• On Monday, November 24th, Andrew Polovin sold 12,874 shares of Tempus AI stock. The stock was sold at an average price of $75.00, for a total transaction of $965,550.00.

Tempus AI Stock Performance

NASDAQ:TEM opened at $58.37 on Friday. The firm’s fifty day simple moving average is $62.35 and its 200-day simple moving average is $73.50. The company has a quick ratio of 3.12, a current ratio of 3.28 and a debt-to-equity ratio of 2.45. The stock has a market cap of $10.38 billion, a PE ratio of -49.05 and a beta of 5.22. Tempus AI, Inc. has a fifty-two week low of $36.22 and a fifty-two week high of $104.32.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the company. Piper Sandler decreased their price target on Tempus AI from $105.00 to $80.00 and set a “neutral” rating on the stock in a research note on Tuesday, November 11th. Needham & Company LLC upped their target price on Tempus AI from $70.00 to $100.00 and gave the company a “buy” rating in a report on Wednesday, November 5th. Robert W. Baird started coverage on Tempus AI in a research report on Tuesday. They issued an “outperform” rating and a $59.00 price target for the company. Canaccord Genuity Group cut their price target on Tempus AI from $95.00 to $80.00 and set a “buy” rating for the company in a research note on Monday, December 22nd. Finally, HC Wainwright lowered their price objective on shares of Tempus AI from $98.00 to $89.00 and set a “buy” rating on the stock in a research note on Friday, November 7th. Eight analysts have rated the stock with a Buy rating, six have given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, Tempus AI currently has a consensus rating of “Hold” and an average price target of $85.92.

Tempus AI News Roundup

Here are the key news stories impacting Tempus AI this week:

• Positive Sentiment: Tempus launched a pan‑cancer HRD‑RNA algorithm intended to improve tumor detection and HRD calling — the product release is being cited as a direct catalyst for recent upside in the stock. Tempus Shares Jump On AI Cancer Tool
• Positive Sentiment: Company is rolling out new AI tools across oncology, cardiology and mental health, signaling commercialization breadth beyond sequencing and bolstering the growth narrative that investors are rewarding. AI-Driven Innovation Accelerates Tempus AI’s Expansion Across MedTech
• Positive Sentiment: Mizuho initiated coverage with an “outperform” and a $100 price target, providing a high‑profile bullish endorsement that likely supported recent buying interest. Mizuho initiation coverage
• Neutral Sentiment: Research coverage by Robert W. Baird started, increasing institutional visibility; new coverage can boost liquidity but doesn’t guarantee directional moves absent model updates. Tempus AI Research Coverage Started at Robert W. Baird
• Neutral Sentiment: Market commentary pieces and a Benzinga options deep‑dive show elevated retail/derivative interest — signals of higher short‑term volatility and active positioning rather than fundamental change. Tempus AI Options Trading: A Deep Dive
• Neutral Sentiment: Analyst and media pieces (Zacks, Forbes) debate valuation and Q4 metrics — spotlighting that Tempus trades at a premium to traditional metrics and remains unprofitable on GAAP, which frames both upside expectation and valuation risk. Is TEM Stock A Buy At $60?
• Negative Sentiment: Despite product and coverage catalysts, fundamentals (negative GAAP profitability, elevated debt/equity) and technicals (current price below both 50‑ and 200‑day moving averages) increase downside risk if sentiment fades or earnings miss expectations. Unlocking Q4 Potential of Tempus

Institutional Trading of Tempus AI

A number of large investors have recently made changes to their positions in TEM. Invesco Ltd. increased its position in Tempus AI by 21.5% during the 4th quarter. Invesco Ltd. now owns 371,674 shares of the company’s stock worth $21,947,000 after purchasing an additional 65,836 shares in the last quarter. Vident Advisory LLC grew its holdings in shares of Tempus AI by 5.3% during the fourth quarter. Vident Advisory LLC now owns 10,376 shares of the company’s stock worth $613,000 after buying an additional 522 shares in the last quarter. Oracle Investment Management Inc. acquired a new position in shares of Tempus AI in the fourth quarter valued at approximately $384,000. EP Wealth Advisors LLC purchased a new position in shares of Tempus AI during the fourth quarter valued at approximately $553,000. Finally, Regal Partners Ltd acquired a new stake in Tempus AI during the fourth quarter worth approximately $531,000. Institutional investors and hedge funds own 24.22% of the company’s stock.

About Tempus AI

Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.

The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.